{"filings":[{"id":3529676,"accession_number":"0001683168-26-007951","cik":1160420,"company_name":"Adia Nutrition, Inc.","ticker":"ADIA","form_type":"8-K","filed_at":"2026-10-19T15:22:28+00:00","items":["1.01","9.01"],"status":"ready","headline":"Adia Med sells 7% of Adia Labs LLC to CEO Larry Powalisz for $350,000 cash in related-party deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Adia Med sold 7 of 100 units in subsidiary Adia Labs LLC to CEO Larry Powalisz for $350,000 cash, or $50,000 per unit, per the Oct 13, 2026 agreement.","The units carry a 7% membership interest and 7% of total voting power (one vote per unit of 100); operating agreement to be amended at closing.","Related-party terms: Powalisz buys as an individual; independent directors Monica Sher, M.D. and Richard Edwards, D.O. signed for Adia Med and must jointly approve in writing any use of the proceeds.","Powalisz has no unilateral authority to direct spending of the purchase price or to approve/execute amendments on the seller's behalf.","Closing needs full wire payment plus buyer joinder and updated cap table; deal terminates if not closed within 10 days of effectiveness. Live Oak Health (QCM Biologics) consented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3412396,"accession_number":"0001683168-26-007770","cik":1160420,"company_name":"Adia Nutrition, Inc.","ticker":"ADIA","form_type":"8-K","filed_at":"2026-10-13T11:46:08+00:00","items":["1.02","9.01"],"status":"ready","headline":"Adia Med repays CEO Larry Powalisz's $1M related-party credit line in full for $934,970.94","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On October 9, 2026 Adia Med fully repaid and discharged its unsecured revolving line of credit from CEO Larry Powalisz, originally dated June 30, 2024.","Total paid to the lender was $934,970.94: $500,000 on October 7, 2026 and $434,970.94 on October 9, 2026.","The October 9 payment included $74,658.94 of accrued interest; the balance went to principal, and the facility bore interest at 6% per annum calculated daily.","The facility had been increased over time to a $1,000,000 commitment to accommodate the company's growth needs.","Powalisz acknowledged via the Paid-in-Full Acknowledgment (Exhibit 10.1) that principal and interest are satisfied in full as of October 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3273085,"accession_number":"0001683168-26-007632","cik":1160420,"company_name":"Adia Nutrition, Inc.","ticker":"ADIA","form_type":"8-K","filed_at":"2026-10-05T23:16:34+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Adia Med sells 30% of Adia Labs LLC to Live Oak Health for $1.5M; keeps 70% economics but gives 50% voting power","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Adia Med sold 30 of 100 units in Adia Labs LLC (30%) to Live Oak Health LLC d/b/a QCM Biologics at $50,000 per unit, or $1,500,000 total, closing September 30, 2026.","$1,000,000 was paid in cash; $500,000 via a promissory note at 7% interest with $2,916.67 monthly interest-only payments for 48 months, balloon due September 30, 2030, secured by the units.","Buyer has an option through September 30, 2028 to buy 10 more units at $50,000 each ($500,000 total); full exercise would leave Adia Med with 60% economic ownership.","Despite 70/30 economic ownership, Adia Med and Live Oak each hold 50% of voting power on member matters; Adia Labs LLC will have two managers, one appointed by each member.","The pact includes a first right of refusal for Adia Labs LLC, quarterly distributions of 90% of cash after expenses with a 10% reserve, and Florida governing law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3265996,"accession_number":"0001683168-26-007624","cik":1160420,"company_name":"Adia Nutrition, Inc.","ticker":"ADIA","form_type":"8-K","filed_at":"2026-10-05T20:49:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADIA Med sues Tydus Richards and 12 others to quiet title in 29,059,792 shares, 30.78% of common","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["ADIA Med filed a verified complaint September 28, 2026 in Seminole County, Florida Circuit Court, Case No. 2026CA002155, against Tydus Richards and 12 other claimants.","The action seeks to quiet title in 29,059,792 shares, or 30.78% of issued and outstanding non-preferred common stock, valued at $3,487,175.04 at the August 13, 2026 close.","A ruling for the company could reduce shares deemed issued and outstanding by up to 29,059,792; ADIA says it will not treat the shares as retired unless a court orders it.","The complaint alleges a January 2024 change of control when Legends Investment Properties LLC acquired all Special 2022 Series A Preferred stock carrying 60% of voting rights.","No responsive pleading or hearing is set; other named claimants include Wen Peng, Teibs Asia Limited, Golden Communications Inc., Revete Capital Partners LLC and Vector Group International LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2421197,"accession_number":"0001683168-26-006679","cik":1160420,"company_name":"Adia Nutrition, Inc.","ticker":"ADIA","form_type":"8-K","filed_at":"2026-08-24T12:00:28+00:00","items":["1.01","9.01"],"status":"ready","headline":"Adia Nutrition engages Lucosky Brookman for NASDAQ uplist and bridge financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engagement letter dated Aug 14, 2026; fixed fee $150,000 for uplist and bridge financing services.","Fee payable: $30k on bridge financing close, $50k on S-1 filing, remainder on uplisting close.","SEC compliance services billed $8,000/month after listing on Nasdaq or NYSE.","Company plans uplisting from OTC to NASDAQ Capital Market or similar senior exchange.","Firm may receive common shares as payment; security interest in company assets granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2297636,"accession_number":"0001683168-26-006525","cik":1160420,"company_name":"Adia Nutrition, Inc.","ticker":"ADIA","form_type":"8-K","filed_at":"2026-08-17T18:56:05+00:00","items":["5.03","9.01"],"status":"ready","headline":"Adia Nutrition changes name to Adia Med, Inc.; ticker ADIA unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corporate name changed from Adia Nutrition, Inc. to Adia Med, Inc., effective June 2, 2026.","Certificate of Amendment filed with Nevada Secretary of State; Articles amended to reflect new name.","FINRA approved name change on July 10, 2026; common stock continues trading as ADIA on OTC Markets.","Outstanding stock certificates remain valid; no exchange required. Future filings under new name."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}